Clinical Trial Update: Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of MK-5592 (Posaconazole) in Japanese participants with fungal infection (Aspergillosis) has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis

Drugs mentioned

• MK-5592 (Posaconazole) (posaconazole)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Aspergillosis | Phase 3 | Status: COMPLETED | Results posted: 2019-01-11